Digital Therapeutics Market to Reach US$ 39.52 Billion by 2033 at 21.6% CAGR; North America Leads with 43% Share - Key Players: Livongo Health, Medtronic, Omada Health, Pear Therapeutics

The Global Digital Therapeutics Market reached US$ 6.84 billion in 2024 and is projected to grow to US$ 39.52 billion by 2033, registering a CAGR of 21.6 percent during the forecast period 2025 to 2033. Digital therapeutics leverage software and connected devices to deliver evidence-based interventions for disease prevention, management and treatment. The market offers diverse service models, ranging from fully integrated ecosystems combining hardware, software and clinical support to modular Software-as-a-Service platforms. This adaptability supports broad adoption among healthcare providers, payers and patient populations, positioning digital therapeutics as a key driver of innovation in chronic disease management and healthcare delivery.

Market growth is further reinforced by recent product launches and expanding clinical applications. For example, in April 2025, Teladoc Health introduced its Next Generation Cardiometabolic Health Program aimed at improving population health and addressing obesity, diabetes and hypertension. Such initiatives illustrate how leading companies are deploying digital therapeutics to manage both individual conditions and broader, population-level chronic disease challenges. With ongoing technological advancements and increasing integration into healthcare systems, the digital therapeutics market is expected to sustain strong growth in the coming years.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/digital-therapeutics-market?sai-v
The Digital Therapeutics Market refers to the industry focused on evidence-based software-driven interventions designed to prevent, manage, or treat medical conditions and improve patient health outcomes.

Key Developments
✅ October 2025: Leading U.S. digital therapeutics companies expanded real-world evidence programs to assess long-term efficacy and adherence of prescription DTx solutions for chronic disease management.

✅ September 2025: Healthcare providers in North America integrated AI-driven patient engagement platforms with digital therapeutics apps to personalize therapy for diabetes, cardiovascular, and mental health conditions.

✅ August 2025: European hospitals adopted mobile-based DTx platforms for remote monitoring and behavioral interventions, improving patient compliance and outcomes.

✅July 2025: Asia-Pacific healthcare networks implemented telehealth-integrated digital therapeutics systems to enhance accessibility for rural and underserved populations.

✅ May 2025: Major global DTx vendors launched multilingual, gamified therapeutic apps to improve adherence and engagement for patients with chronic lifestyle diseases.

✅ March 2025: Research institutions collaborated with DTx developers to validate clinical outcomes of digital cognitive-behavioral therapy (CBT) programs across diverse patient cohorts.

Mergers & Acquisitions
✅November 2025: A U.S.-based digital therapeutics leader acquired a clinical-stage DTx startup specializing in AI-driven behavioral health interventions to strengthen its product pipeline.

✅ August 2025: A European digital health company partnered with a North American telemedicine provider to co-develop integrated DTx platforms for chronic disease management.

✅ June 2025: A global healthcare technology firm acquired a mobile-based DTx platform developer to expand its portfolio of prescription digital therapeutics and patient monitoring solutions.

Key Players
2Morrow Inc. | Livongo Health, Inc. | Medtronic Plc. | Omada Health, Inc. | Pear Therapeutics, Inc. | Proteus Digital Health, Inc. | ResMed, Inc. (Propeller Health) | Voluntis, Inc. | Welldoc, Inc.

Key Highlights
2Morrow Inc. - Holds an estimated 6.2% share, driven by its digital behavioral health programs, mobile health interventions, and growing adoption in smoking cessation and chronic disease management.

Livongo Health, Inc. - Accounts for around 15.4% share, supported by its AI-driven chronic disease management platform, real-time patient monitoring, and integration with remote care programs.

Medtronic Plc. - Maintains approximately 12.9% share, fueled by its connected devices, diabetes management solutions, and extensive global medical technology infrastructure.

Omada Health, Inc. - Represents nearly 9.7% share, recognized for its digital behavioral and chronic condition programs, personalized coaching, and strong payer-provider collaborations.

Pear Therapeutics, Inc. - Holds about 7.6% share, driven by its prescription digital therapeutics (PDTs), regulatory approvals for behavioral and neurological conditions, and partnerships with healthcare providers.

Proteus Digital Health, Inc. - Accounts for around 5.1% share, supported by its ingestible sensors, adherence tracking technology, and integration with remote patient monitoring platforms.

ResMed, Inc. (Propeller Health) - Maintains roughly 14.3% share, strengthened by its respiratory monitoring solutions, IoT-connected inhalers, and widespread adoption in asthma and COPD management.

Voluntis, Inc. - Represents approximately 6.4% share, driven by its digital therapeutics and connected device solutions, targeting oncology and diabetes therapy adherence.

Welldoc, Inc. - Holds an estimated 8.2% share, fueled by its BlueStar diabetes management platform, strong FDA clearance, and partnerships with healthcare payers and providers.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=digital-therapeutics-market?sai-v

Market Drivers

- Rising prevalence of chronic diseases and lifestyle disorders such as diabetes, cardiovascular diseases, and obesity driving demand for digital therapeutic solutions.

- Growing adoption of mobile health applications and wearable devices enabling remote monitoring and personalized interventions.

- Increasing awareness among healthcare providers and patients about evidence-based digital treatment options.

- Advancements in AI, machine learning, and behavioral analytics enhancing the efficacy of digital therapeutics.

- Expansion of telemedicine and remote patient care models supporting integration of digital therapeutic programs.

- Rising focus on preventive healthcare and patient-centric treatment approaches encouraging the use of DTx solutions.

- Supportive reimbursement policies and regulatory approvals facilitating market growth.

Industry Developments

- Launch of prescription-based digital therapeutic apps targeting chronic disease management and mental health.

- Strategic partnerships between pharmaceutical companies and digital health startups to co-develop DTx solutions.

- Increased investment in clinical trials and real-world evidence (RWE) studies to validate efficacy and secure regulatory clearance.

- Development of integrated platforms combining digital therapeutics with traditional healthcare services for comprehensive care.

- Expansion of AI-driven behavior modification programs and gamified interventions for better patient adherence.

- Growing availability of DTx solutions for remote patient monitoring and disease prevention.

Regional Insights

North America - 43% share: "Driven by high adoption of digital health technologies, advanced healthcare infrastructure, and strong investments in DTx innovation."

Europe - 28% share: "Supported by increasing regulatory approvals, growing telemedicine adoption, and rising awareness of chronic disease management."

Asia Pacific - 23% share: "Fueled by growing smartphone penetration, government initiatives promoting digital health, and rising prevalence of lifestyle disorders."

Latin America - 4% share: "Boosted by expanding digital health infrastructure and increasing acceptance of mobile health interventions."

Middle East & Africa - 2% share: "Driven by emerging healthcare digitalization projects and gradual adoption of remote patient monitoring solutions."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/digital-therapeutics-market?sai-v

Key Segments

➥ By Product Type
• Software: Includes digital health platforms, mobile apps, analytics tools, and AI-enabled solutions for monitoring, managing, and improving patient outcomes.
• Devices: Encompasses wearable sensors, glucose monitors, smart inhalers, and other connected medical devices that track physiological parameters and support disease management.
• Others: Covers telehealth solutions, remote monitoring kits, and ancillary tools that complement core software and device offerings.

➥ By Application
• Diabetes: Solutions for glucose monitoring, insulin management, lifestyle tracking, and personalized care plans.
• Obesity: Tools for weight management, dietary monitoring, activity tracking, and behavioral interventions.
• Cardiovascular Diseases (CVD): Platforms and devices for heart rate monitoring, blood pressure tracking, arrhythmia detection, and cardiac rehabilitation.
• Central Nervous System (CNS) Diseases: Digital therapeutics and monitoring solutions for neurological disorders such as Parkinson's, Alzheimer's, and epilepsy.
• Respiratory Diseases: Devices and software for asthma, COPD, and other respiratory conditions, enabling real-time tracking and treatment adherence.
• Smoking Cessation: Digital programs and mobile apps to support behavior change, monitoring, and intervention for tobacco users.
• Gastrointestinal Disorders (GID): Tools for managing gut health, tracking symptoms, and supporting dietary interventions.
• Others: Includes digital solutions for sleep disorders, chronic pain, mental health, and other emerging health conditions.

➥ By Sales Channel
• Business-to-Business (B2B): Products and solutions distributed to organizations such as employers, healthcare providers, payers, pharmaceutical companies, and others, enabling corporate wellness programs, clinical integration, and large-scale patient management initiatives.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.